Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > CNS Agents > Ropinirole hydrochloride for Sale > Ropinirole Hydrochloride API - A Dopamine Agonist for Parkinson's Disease Treatment.
Ropinirole Hydrochloride API - A Dopamine Agonist for Parkinson's Disease Treatment. buy - large image1
Ropinirole Hydrochloride API - A Dopamine Agonist for Parkinson's Disease Treatment. buy - image1
Ropinirole Hydrochloride API - A Dopamine Agonist for Parkinson's Disease Treatment. buy - image2
Ropinirole Hydrochloride API - A Dopamine Agonist for Parkinson's Disease Treatment. buy - image3
Ropinirole Hydrochloride API - A Dopamine Agonist for Parkinson's Disease Treatment. buy - image4

Ropinirole Hydrochloride API - A Dopamine Agonist for Parkinson's Disease Treatment.

Unit Price: Get Latest Price
CAS No.:

91374-20-8

Grade:

Pharmaceutical Grade

Content:

101%

Port:

Qingdao

Brand:

Tianrui

Packaging:

Sealed fiber drum

Price valid (until):

2025-11-12

Company Type:
Manufactory
Location:
China
Qualification:
Main Products:

APIs

  • Product Description

  • Seller Information

  • Description


      About  Product   


    Ropinirole Hydrochloride (CAS: 91374-21-9) is a high-purity active pharmaceutical ingredient (API) that functions as a non-ergot dopamine agonist. Specifically developed for the treatment of Parkinson's disease and restless legs syndrome, it demonstrates excellent efficacy in managing neurological symptoms. Manufactured by Hefei TianRui Pharmaceutical under strict cGMP conditions, our Ropinirole Hydrochloride API guarantees high purity, low impurity profiles, and reliable quality for central nervous system drug formulations.

    Items Specifications
    Product Name Ropinirole Hydrochloride
    CAS Registry Number 91374-21-9
    IUPAC Name 4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride
    Molecular Weight 296.84 g/mol
    Solubility It is soluble in water, soluble in methanol, and slightly soluble in ethanol.
    Melting Point 243-250°C
    Primary Use Treatment of Parkinson's disease
    Treatment for restless legs syndrome
    Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 1 Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 2
    Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 3

    Company Profile

    • Founded: 2014

    • Focus: High-tech enterprise specializing in the development and industrialization of small-molecule pharmaceutical synthesis technology

    • Facilities:

      • Two workshops (TR1 & TR2) with total capacity ≈ 1000 tons/year

      • Reactors: 3000L×15, 2000L×10, and numerous smaller reactors (1000L, 500L, 100L)

      • Ultra-low temperature cryogenic reactor (explosion-proof workshop included)

      • GMP workshop & clean room

    • QC Lab Equipment: GC×2, HPLC×3, UV, IR, KF titrator, etc.

    • Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 4

    • Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 5
    • Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 6


      About  company  


    Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 7

    In 2015, the company developed polypeptide absorbent permeation enhancers: ethyl 8-bromo-octanoate and Carsalam, which is the 1st and only qualified Chinese supplier of Semaglutide to meet the internal control requirements of innovator Novo Nordisk.

    In 2020, the company independently developed and optimized 8-bromo-octanoic acid and 6-bromo-caproic acid to become a COVID-19 vaccine carrier manufacturer and supplier to Moderna company, contributing its share to the fight against COVID-19.

    In 2022, Tianrui R&D Center and cGMP manufacturing facility was inaugurated and put into operation. And in the same year, polypeptide absorbent permeation enhancers SNAC (Salcaprozate Sodium) has successfully obtained the domestic CDE registration number (F20220000072) and the US FDA registration number (037135), and another batch of innovative APIs and pharmaceutical excipients are under registration and approval.

    Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 8 Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 9

    Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 10

    Basic Info
    Product Name:

    Ropinirole hydrochloride

    Other Name:

    2H-Indol-2-one,4-[2-(dipropylamino)ethyl]-1,3-dihydro-,hydrochloride (1:1);2H-Indol-2-one,4-[2-(dipropylamino)ethyl]-1,3-dihydro-,monohydrochloride;SKF 101468 hydrochloride;Ropinirole hydrochloride;SKF 101468A;Requip;Parkirop;Ropitar;Ropark;Repreve;Ronirol;Adartrel;Spiroco XL;Ralnea XL;Clevor;115616-44-9

    CAS No.:

    91374-20-8

    Molecular Formula:

    C16H24N2O.ClH

    InChIKeys:

    InChIKey=XDXHAEQXIBQUEZ-UHFFFAOYSA-N

    Molecular Weight:

    296.84

    Exact Mass:

    296.165527

    EC Number:

    1308068-626-2

    UNII:

    D7ZD41RZI9

    DSSTox ID:

    DTXSID50238533

    NCI Thesaurus Code:

    C47710

    ATC Code:

    QN04BC04

    HScode:

    2933790090

    Categories:

    CNS Agents

    Characteristics
    PSA:

    32.3

    XLogP3:

    3.78570

    Appearance:

    light yellow

    Melting Point:

    241-243 °C

    Boiling Point:

    410.5°C at 760 mmHg

    Water Solubility:

    H2O: >10mg/mL

    Storage Conditions:

    room temp

    Hazard Identification

    Classification of the substance or mixture

    Acute toxicity - Category 4, Oral

    Hazardous to the aquatic environment, short-term (Acute) - Category Acute 1

    GHS label elements, including precautionary statements

    Pictogram(s)
    Signal word

    Warning

    Hazard statement(s)

    H302 Harmful if swallowed

    H400 Very toxic to aquatic life

    Precautionary statement(s)
    Prevention

    P264 Wash ... thoroughly after handling.

    P270 Do not eat, drink or smoke when using this product.

    P273 Avoid release to the environment.

    Response

    P301+P317 IF SWALLOWED: Get medical help.

    P330 Rinse mouth.

    P391 Collect spillage.

    Storage

    none

    Disposal

    P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    APIs

    Location:

    No.23,lntersection of Fenglehe Avenue and Leiyang Road, Huagang Town,Feixi County, Hefei, Anhui, China.

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    15

    Total Annual Revenue:

    $50 million-$100 million

    Total Employees:

    11-50

    Year of Establishment:

    2014


    About TianRui  


    Hefei TianRui Pharmaceutical Chemical Co., Ltd was founded in 2014 as a high-tech enterprise focused on the development and industrialization of pharmaceutical small molecule synthesis technology. Our workshop and R&D center are located in Hefei HuaGang Provincial Industrial Park, Anhui Province. We are committed to providing professional technical services and commercialization of small molecule specialty APIs, CGMP standard intermediates, and functional pharmaceutical excipients and MRNA vaccine vectors for domestic and overseas well-known pharmaceutical companies.


      Main Events  


    In 2015, the company developed polypeptide absorbent permeation enhancers: ethyl 8-bromo-octanoate and Carsalam, which is the 1st and only qualified Chinese supplier of Semaglutide to meet the internal control requirements of innovator Novo Nordisk.


    In 2020, the company independently developed and optimized 8-bromo-octanoic acid and 6-bromo-caproic acid to become a COVID-19 vaccine carrier manufacturer and supplier to Moderna company, contributing its share to the fight against COVID-19.


    In 2022, Tianrui R&D Center and cGMP manufacturing facility was inaugurated and put into operation. And in the same year, polypeptide absorbent permeation enhancers SNAC (Salcaprozate Sodium) has successfully obtained the domestic CDE registration number (F20220000072) and the US FDA registration number (037135), and another batch of innovative APIs and pharmaceutical excipients are under registration and approval.

  • Country Product Purchase Quantity Date Posted
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.